A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma
Plain-language summary
This trial is testing selinexor combined with pegaspargase and dexamethasone for patients with extranodal NK/T-cell lymphoma (ENKTL) who have been newly diagnosed and have not yet received treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Sintilimab (DRUG): Sintilimab will be given at 200 mg by intravenous infusion. | Pegaspargase (DRUG): Pegaspargase will be given at 2000 U/m², with a maximum total dose of 3750 U, by intramuscular injection. | Selinexor (DRUG): Selinexor will be given orally once weekly at 60mg. | radiotherapy (RADIATION): Patients will receive induction treatment for up to 4 cycles, followed by radiotherapy.
Sintilimab, Pegaspargase, Selinexor, radiotherapy
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details